MolGenie is using and developing compound design technologies aiming at drug-like and selective small molecules that exhibit a clear structure-activity relationship and have the promise of good tolerability and oral bioavailability. MolGenie has been formed in 2021 to use its network of experts in drug discovery and development to advance interesting new therapeutic agents towards IND applications.
“Form ever follows function” – this Louis Sullivan principle is our guiding principle for compound design and engineering.
The compound design process includes the following principal stages:
First, the protein binding pocket is identified and a complementary imprint is calculated, holding properties, such as charge, polarizability, etc.
Second, molecules that satisfy the needs of the binding pocket are designed – this includes the selection of intellectual property generating chemistries and building blocks.
Third, molecules that have a good bioavailability, solubility and managed metabolic stability are selected. Furthermore, a broad screening for potential side and off-target effects is performed
about the company:
The company was started in Stuttgart, Germany, on February 23, 2021. It offers drug discovery services and develops its own intellectual property for selected biological targets and diseases.